Voriconazole
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Voriconazole: From Fungal Infections to Multidrug-Resistant Tuberculosis
One-Sentence Summary
Voriconazole is a triazole antifungal agent used to treat invasive fungal infections (e.g., aspergillosis, candidiasis) by inhibiting fungal CYP450-dependent 14α-demethylase and blocking ergosterol synthesis. The TxGNN model’s top-ranked prediction is Multidrug-Resistant Tuberculosis (MDR-TB), but this pairing is currently supported by 0 clinical trials and only 3 tangentially related publications, none of which describe voriconazole as a treatment for tuberculosis itself. The evidence pack’s own mechanistic analysis flags this prediction as a likely false positive driven by knowledge-graph co-occurrence noise rather than genuine pharmacological relevance.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in available regulatory data; drug class identified as triazole antifungal (invasive fungal infections) |
| Predicted New Indication | Multidrug-Resistant Tuberculosis |
| TxGNN Prediction Score | 98.67% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed MOA data in the standard field is a data gap, but the evidence pack’s rationale text identifies voriconazole as a triazole antifungal whose mechanism is inhibition of fungal 14α-demethylase and blockade of ergosterol synthesis. This mechanism has no known antimycobacterial activity — it does not act on any target relevant to Mycobacterium tuberculosis.
The literature retrieved for this pairing consistently describes patients with MDR-TB who also develop a fungal co-infection (aspergilloma, invasive aspergillosis) in TB-damaged lung cavities. In these cases, voriconazole is used to treat the fungal co-infection, not the tuberculosis itself. The TxGNN model appears to have picked up this frequent clinical co-occurrence in the literature as a spurious drug–disease association, rather than a genuine treatment relationship.
Consequently, this prediction should be interpreted as a likely false positive: the pharmacological mechanism does not support efficacy against MDR-TB, and no clinical trial or direct treatment evidence exists. A more mechanistically defensible reframing — supported by a lower-ranked signal in this same evidence pack (rank 8, “inactive tuberculosis,” L4, decision stage S1, “Research Question”) — is that voriconazole may have a legitimate secondary role in treating chronic pulmonary aspergillosis arising in post-TB lung cavities, which is a distinct clinical entity from tuberculosis itself and would require re-scoping the indication target.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18992166 | 2008 | Case Report | Cases Journal | MDR-TB coexisting with aspergilloma/invasive aspergillosis in a diabetic patient; voriconazole was used to treat the fungal co-infection, not the tuberculosis itself |
| 37145297 | 2023 | Case Report/In-vitro | Braz J Microbiol | In-vitro study of photodynamic inactivation against multidrug-resistant Fonsecaea nubica (chromoblastomycosis); does not involve voriconazole or tuberculosis |
| 39359062 | 2024 | Basic Research | Virulence | Genetic diversity study of fluconazole-resistant Candida krusei; unrelated to M. tuberculosis or voriconazole treatment |
None of these publications provide direct evidence that voriconazole treats tuberculosis; all relate to fungal pathogens co-occurring with TB or unrelated to TB entirely.
EU Market Information
This product currently holds no EU marketing authorization on record (market status: not marketed, 0 authorizations).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link between voriconazole (antifungal, ergosterol-synthesis inhibitor) and multidrug-resistant tuberculosis (a mycobacterial infection) is absent. All retrieved literature describes fungal co-infections occurring alongside TB rather than voriconazole treating TB directly, and no clinical trials exist for this pairing. This is assessed as a likely knowledge-graph false positive (evidence level L5).
To proceed, the following is needed:
- TFDA/SmPC label data (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism-of-action documentation from DrugBank
- If pursuing a related, more plausible signal: re-scope the candidate indication to “chronic pulmonary aspergillosis in post-TB cavitary lung disease” (supported by rank 8 evidence, L4) rather than tuberculosis itself, and gather targeted clinical evidence for that reframed indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.